This Analyst Is Bullish On Evolent Health's Recent Deal, Calls 'Highly Strategic Acquisition'

• Thursday after close, Evolent Health Inc (NYSE: EVH) agreed to acquire Magellan Specialty Health, the specialty benefit management organization owned by Centene Corporation (NYSE: CNC), for $650 million at the close plus additional contingent consideration of up to $150 million based on 2023 performance.

• William Blair is positive on the acquisition and believes this is consistent with management's prior commentary that Evolent would consider strategic assets that fit under the specialty care management segment and provide a leg into new specialties beyond oncology, MSK, and cardiology.

• The firm reiterates the Outperform rating.

• EVH shares now trade at roughly 1.5 times the analyst's 2023 sales forecast, which is an attractive risk/reward level for the stock, given the company's unique market position, large and growing addressable market, and still-robust longer-term growth outlook.

• Moreover, William Blair says that the pandemic could accelerate the push to value-based care as providers move away from volume-based, fee-for-service reimbursement.

• Price Action: EVH shares are up 15.47% at $27.55 on the last check Friday.

Latest Ratings for EVH

Date	Firm	Action	From	To
Nov 2021	JP Morgan	Upgrades	Neutral	Overweight
Aug 2021	Canaccord Genuity	Maintains		Buy
Mar 2021	Canaccord Genuity	Maintains		Buy

View More Analyst Ratings for EVH

View the Latest Analyst Ratings

See more from Benzinga

• Centene Agrees To Divest Magellan Specialty Health To Evolent Health

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.